CD19 and B-cell chronic lymphocytic leukemia: Another clinical anti-CD19 CAR T cell trial treated CLL patients with ibrutinib more than 2 weeks prior to leukapheresis and proceeded with the treatment for more than 3 months after administration of CAR T cells [97].